EGFR and lung adenocarcinoma: Mutations in RIT1 are mutually exclusive with mutations in KRAS, EGFR, ALK, MET, and other driver oncogenes in lung adenocarcinoma, suggesting that RIT1 may drive EGFR/RAS pathway activation in RIT1-mutant tumors6.